Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (TA655)
Evidence-based recommendations on nivolumab (Opdivo) for advanced squamous non-small-cell lung cancer in adults after chemotherapy
Evidence-based recommendations on nivolumab (Opdivo) for advanced squamous non-small-cell lung cancer in adults after chemotherapy
Evidence-based recommendations on siponimod (Mayzent) for treating secondary progressive multiple sclerosis in adults
Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults
Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis (CBC / cirrhosis) in adults
NICE is unable to make a recommendation about the use in the NHS of afatinib for advanced squamous non-small-cell lung cancer after platinum-based chemotherapy
Evidence-based recommendations on Holoclar for treating limbal stem cell deficiency in adults after eye burns
Evidence-based recommendations on glycoprotein IIb/IIIa inhibitors(abciximab [ReoPro], eptifibatide [Integrilin], tirofiban [Aggrastat]) for acute coronary
NICE was unable to make a recommendation about the use in the NHS of elotuzumab for previously treated multiple myeloma because no evidence submission was
NICE was unable to make a recommendation about the use in the NHS of tenofovir alafenamide for treating chronic hepatitis B because no evidence submission was
NICE was unable to make a recommendation about the use in the NHS of bevacizumab for epidermal growth factor receptor mutation-positive non-small-cell lung
NICE is unable to make a recommendation about the use of ibrutinib with bendamustine and rituximab for relapsed or refractory chronic lymphocytic leukaemia
NICE is unable to make a recommendation about the use in the NHS of alectinib for anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Evidence-based recommendations on inhaled corticosteroids (ICSs) for chronic asthma in children aged under 12
Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults
Evidence-based recommendations on pemetrexed (Alimta) for treating non-small-cell lung cancer (NSCLC)
Evidence-based recommendations on bortezomib monotherapy (Velcade) for treating relapsed multiple myeloma in adults
Evidence-based recommendations on bevacizumab (Avastin) and cetuximab (Erbitux) for treating metastatic colorectal cancer
Evidence-based recommendations on gemcitabine for treating metastatic breast cancer in adults
Evidence-based recommendations on methadone and buprenorphine for the management of opioid dependence
Evidence-based recommendations on ustekinumab (Stelara) for treating moderate to severe psoriasis in adults
Evidence-based recommendations on pemetrexed for untreated non-small-cell lung cancer in adults
Evidence-based recommendations on infliximab (Remicade) for acute exacerbations of ulcerative colitis in adults
Evidence-based recommendations on sunitinib (Sutent) for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Evidence-based recommendations on lenalidomide (Revlimid) for treating multiple myeloma in adults who have had at least 2 prior therapies
Evidence-based recommendations on tenofovir disoproxil (Viread) for the treatment of chronic hepatitis B (HBV)
Evidence-based recommendations on rituximab (MabThera) for the first-line treatment of chronic lymphocytic leukaemia (CLL)
Evidence-based recommendatrions on alitretinoin (Toctino) for treating severe chronic hand eczema in adults
Evidence-based recommendations on febuxostat (Adenuric) for the management of hyperuricaemia in people with gout
Evidence-based recommendations on evacizumab (Avastin), soradenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for renal cell carcinoma
Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours (cancer of stomach/digestive system)
Evidence-based recommendations on topotecan (Hycamtin) for treating relapsed small-cell lung cancer (SCLC)
Evidence-based recommendations on machine perfusion systems and cold static storage of kidneys from deceased donors
Evidence-based recommendations on amantadine (Lysovir, Symmetrel), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza (flu)
Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma (tumours/cancer)
Evidence-based recommendations on streptokinase (Streptase), alteplase (Actilyse), reteplase (Rapilysin) and tenecteplase (Metalyse) for early thrombolysis in
Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis (MS) in adults
Evidence-based recommendations on using Intrabeam radiotherapy during breast-conserving surgery in adults
Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C (HCV) in adults
Evidence-based recommendations on ultrasound locating devices for placing central venous catheters into the internal jugular vein
NICE is unable to make a recommendation on duvelisib (Copiktra) for treating relapsed follicular lymphoma after 2 or more systemic therapies in adults because
NICE is unable to make a recommendation about the use in the NHS of eculizumab (Soliris) for treating relapsing neuromyelitis optica because Alexion Pharma UK
Evidence-based recommendations on nalmefene (Selincro) for reducing alcohol consumption in people with alcohol dependence
Evidence-based recommendations on imatinib (Glivec) for adjuvant treatment of gastrointestinal stromal tumours (cancers in the digestive track)
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treatment and secondary prevention of deep vein thrombosis (DVT) or pulmonary embolism
Evidence-based recommendations on total hip replacement and resurfacing arthroplasty for treating end-stage arthritis of the hip
Evidence-based recommendations on aflibercept (Eylea) for visual impairment caused by macular oedema secondary to central retinal vein occlusion
Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)
NICE is unable to make recommendations about regorafenib for metastatic colorectal cancer because no evidence submission was received from Bayer for the..
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing adverse outcomes after acute management of acute coronary syndrome (ACS)
Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes